Sorafenib/piroxicam therapy with biomarker-defined survival benefit in canine muscle-invasive urothelial carcinoma.

Maeda S, Yokota S, Komori M, Goto-Koshino Y, Chambers JK, Uchida K, Yonezawa T, Momoi Y

DOI: 10.1038/s41598-026-64955-1
Published: 2026 Sep 1
Container: Scientific reports
Publisher: Not recorded
Open access: yes

Credibility signals

limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
supportingOpen access status: Normalized open-access status: open. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1038/s41598-026-64955-1,
  title = {Sorafenib/piroxicam therapy with biomarker-defined survival benefit in canine muscle-invasive urothelial carcinoma.},
  author = {Maeda S and Yokota S and Komori M and Goto-Koshino Y and Chambers JK and Uchida K and Yonezawa T and Momoi Y},
  year = {2026},
  journal = {Scientific reports},
  doi = {10.1038/s41598-026-64955-1},
  url = {https://doi.org/10.1038/s41598-026-64955-1}
}

RIS

TY  - JOUR
TI  - Sorafenib/piroxicam therapy with biomarker-defined survival benefit in canine muscle-invasive urothelial carcinoma.
AU  - Maeda S
AU  - Yokota S
AU  - Komori M
AU  - Goto-Koshino Y
AU  - Chambers JK
AU  - Uchida K
AU  - Yonezawa T
AU  - Momoi Y
PY  - 2026
JO  - Scientific reports
DO  - 10.1038/s41598-026-64955-1
UR  - https://doi.org/10.1038/s41598-026-64955-1
ER  -

APA

S, M., S, Y., M, K., Y, G., JK, C., K, U., T, Y., & Y, M. (2026). Sorafenib/piroxicam therapy with biomarker-defined survival benefit in canine muscle-invasive urothelial carcinoma.. Scientific reports. https://doi.org/10.1038/s41598-026-64955-1

Source records

pubmed · retrieved 2026-09-26T01:24:27.385Z